AEON – aeon biopharma, inc. class a (US:NASDAQ)

News

AEON Biopharma Provides Update on Development Pipeline
AEON Biopharma, Inc. (NASDAQ: AEON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
AEON Biopharma, Inc. (NASDAQ: AEON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma Announces Redemption of Public Warrants
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com